Tonix Stock Rises 5% on GPO Deal

Tonix Pharmaceuticals shares jumped about 5.1% after announcing a group purchasing organization coverage agreement effective May 1.
The deal grants TONMYA access to roughly 35 million U.S. commercial lives, about 20% of the 177 million total commercial lives.
TONMYA, launched Nov 2025, is the first FDA‑approved non‑opioid fibromyalgia drug in 15+ years.
The drug is also Medicaid‑covered in 38 states for 55 million lives, representing 73% of Medicaid beneficiaries.